158 / 225
158
· DOS Abstracts
91% infection free survival after cementless one-
stage revision in chronic periprosthetic hip joint in-
fection.
Jeppe Lange
CORIHA RESEARCH GROUP
Background:
Cementless one-stage revision in chronic periprosthetic hip joint
infections has been limited evaluated.
Purpose / Aim of Study:
The purpose of this study was to evaluate a specific
treatment protocol (CORIHA protocol) in this patient group in regards to re-
infection, mortality, revisions for other causes than PJI and to perform failure
analysis in the cases of re-infection.
Materials and Methods:
The study was performed as a multicentre, proof-
of-concept, observational study with prospective data collection. Patients in-
cluded were treated with a cementless one-stage revision according to an a pri-
ori defined treatment algorithm at 8 participating departments of orthopaedic
surgery between 2009 -2014 and enrolled in a 2-year follow-up program. 10
surgeons performed the procedures with no correlation between surgeon and
final outcome. 56 patients were included. All patients had a minimum of 2 years
follow-up with a mean follow-up time from the procedure of 4 years.
Findings / Results:
The cumulative incidence of re-revision due to infection
was 8.9% (CI 3.2%-18.1%). The 1 and 5 year survival incidence was 96% (CI
86%-99%) and 89% (CI 75%-95%). Three patients had an aseptic revision
performed: two patients suffered post-operative periprosthetic fractures man-
aged with a relevant osteosynthesis and one patient had stem subsidence with
exchange performed, none resulted in re-infection. Failure analysis of the 5 re-
infections did not detect a clear pattern as to the cause of failure.
Conclusions:
We found that cementless one-stage revision in chronic peri-
prosthetic hip joint infections has low re- reinfection rates in selected patients
and is readily comparable to published success rates following a two-stage revi-
sion. Cementless one-stage revision in chronic periprosthetic hip joint infections
can be used as a valuable first-line treatment strategy.
No conflicts of interest reported
110.